PARP inhibitors for metastatic breast cancer
Michael Untch - Helios Hospital Berlin-Buch, Berlin, Germany
PARP inhibitors for metastatic breast cancer ( Michael Untch - Helios Hospital Berlin-Buch, Berlin, Germany )
7 Oct 2019
KATHERINE trial updates for HER2-positive breast cancer
Prof Michael Untch - Helios Hospital Berlin-Buch, Berlin, Germany
KATHERINE trial updates for HER2-positive breast cancer ( Prof Michael Untch - Helios Hospital Berlin-Buch, Berlin, Germany )
7 Oct 2019
Highlights from ESMO 2019
Prof Josep Tabernero - ESMO President
Highlights from ESMO 2019 ( Prof Josep Tabernero - ESMO President )
4 Oct 2019
MEDIOLA: Olaparib and durvalumab for germline BRCA-mutated metastatic breast can...
Prof Susan Domchek - University of Pennsylvania, Pennsylvania, USA
MEDIOLA: Olaparib and durvalumab for germline BRCA-mutated metastatic breast cancer ( Prof Susan Domchek - University of Pennsylvania, Pennsylvania, USA )
4 Oct 2019
Phase III study of veliparib with carboplatin and paclitaxel in HER2-negative ad...
Dr Véronique Diéras - Centre Eugène Marquis, Rennes, France
Phase III study of veliparib with carboplatin and paclitaxel in HER2-negative advanced/metastatic gBRCA-associated breast cancer ( Dr Véronique Diéras - Centre Eugène Marquis, Rennes, France )
4 Oct 2019
Using PARP inhibitors to improve quality of life for patients with metastatic br...
Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia
Using PARP inhibitors to improve quality of life for patients with metastatic breast cancer ( Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia )
3 Oct 2019
Analysis of assay used in IMpassion130 to guide treatment of metastatic and adva...
Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia
Analysis of assay used in IMpassion130 to guide treatment of metastatic and advanced breast cancers ( Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia )
3 Oct 2019
Comment: Pembro plus chemo in neoadjuvant and adjuvant treatment for early tripl...
Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia
Comment: Pembro plus chemo in neoadjuvant and adjuvant treatment for early triple-negative breast cancer ( Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia )
29 Sep 2019
Comment: Veliparib with carboplatin and paclitaxel in advanced gBRCA-positive br...
Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia
Comment: Veliparib with carboplatin and paclitaxel in advanced gBRCA-positive breast cancers ( Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia )
29 Sep 2019
KEYNOTE-522: Immunotherapy and chemo for early triple negative breast cancer
Prof Peter Schmid - St Bartholomew's Hospital London, London, UK
KEYNOTE-522: Immunotherapy and chemo for early triple negative breast cancer ( Prof Peter Schmid - St Bartholomew's Hospital London, London, UK )
29 Sep 2019
Comment: Keynote 522 trial
Prof Guiseppe Curigliano - European Institute of Oncology, Milan, Italy
Comment: Keynote 522 trial ( Prof Guiseppe Curigliano - European Institute of Oncology, Milan, Italy )
29 Sep 2019
CDK4/6 inhibitor ribociclib plus fulvestrant improves overall survival in postme...
Prof Dennis Slamon - Ronald Reagan UCLA Medical Center, Los Angeles, California
CDK4/6 inhibitor ribociclib plus fulvestrant improves overall survival in postmenopausal HR-positive HER2-negative breast cancer ( Prof Dennis Slamon - Ronald Reagan UCLA Medical Center, Los Angeles, California )
29 Sep 2019